- Launched in 2009
- Listed in PubMed, PMC, Web of Science, Scopus and DOAJ
- International expert Editorial Board and panel of Associate Editors
- Rigorous and fast peer review
- Rapid online publication (~3 weeks after article acceptance)
Therapeutic Advances in Medical Oncology delivers the highest quality peer-reviewed original research articles, reviews, and scholarly comment on pioneering efforts and innovative studies in the medical treatment of cancer. The journal has a strong clinical and pharmacological focus and is aimed at an international audience of clinicians and researchers in medical oncology, providing an online forum for rapid dissemination of recent research and perspectives in this area.
The editors welcome original research articles across all areas of oncology.
The journal publishes original research articles and review articles primarily. Original research manuscripts may include laboratory, animal or human/clinical studies – all phases. Letters to the Editor and Case Reports will also be considered.
Review articles include expert opinion/perspective reviews (including single-drug and drug class reviews), narrative reviews and therapeutic area reviews. Systematic reviews, meta-analyses, postmarketing and health economic and pharmacoeconomic reviews are also welcomed. The appropriate EQUATOR Network reporting guidelines should be followed (e.g. CONSORT for randomized, controlled trials and PRISMA for systematic reviews/meta-analyses). The journal endorses the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrolment. However, consistent with the AllTrials campaign, retrospectively registered trials will be considered if the justification for late registration is acceptable.
The journal adheres to a blind review process in which the reviewer's name is routinely withheld from the author unless the reviewer requests a preference for their identity to be revealed. Manuscripts are reviewed by at least two referees; a first editorial decision is generally reached within 3 weeks of submission and Online First publication is usually within 3 weeks of Acceptance.
|Georgia Patey||SAGE Publications Ltd, UK|
|Ian Davis||Eastern Health Clinical School, Monash University, Australia|
|Axel Grothey||Mayo Clinic, Rochester, MN, USA|
|Nadia Harbeck||University of Munich, Germany|
|Sara Hurvitz||University of California, Los Angeles, CA, USA|
|Jonathan Ledermann||UCL Cancer Institute, London, UK|
|Karl Lewis||University of Colorado Denver, Denver, CO, USA|
|Keunchil Park||Samsung Medical Center, Sungkyunkwan University School of Medicine, Korea|
|Antonio Rossi||IRCCS Casa Sollievo della Sofferenza, Italy|
|Takayuki Yoshino||National Cancer Center Hospital East, Chiba, Japan|
|Dirk Arnold||Instituto CUF de Oncologia, Lisbon, Portugal|
|Carlos L Arteaga||Vanderbilt University, Nashville, TN, USA|
|Tanya B. Dorff||City of Hope, Duarte, CA, USA|
|Christopher Benz||Buck Institute for Research on Aging, UCSF, Novato, CA, USA|
|Michael Boyer||University of Sydney, Sydney, Australia|
|Kim N Chi||University of British Columbia, Vancouver, BC, Canada|
|Toni K Choueiri||Dana-Farber Cancer Institute, Boston, MA, USA|
|Ronald de Wit||Erasmus University Medical Center, Rotterdam, The Netherlands|
|Wilfried Eberhardt||University Duisburg-Essen, Essen, Germany|
|Tim Eisen||Cambridge University, Cambridge, UK|
|Alfredo Falcone||University of Pisa, Pisa, Italy|
|Michael Findlay||University of Auckland, Auckland, New Zealand|
|Jorge A. Garcia||Cleveland Clinic, Cleveland, OH, USA|
|Cesare Gridelli||S.G. Moscati Hospital, Avellino, Italy|
|Nasser H. Hanna||Indiana University School of Medicine, Indianapolis, IN, USA|
|Paul R Helft||Indiana University School of Medicine, Indianapolis, IN, USA|
|Maha Hussain||Northwestern University Lurie Cancer Center, Chicago, IL, USA|
|David H Ilson||Memorial Sloan-Kettering Cancer Center, New York, NY, USA|
|Sung-Bae Kim||University of Ulsan, Seoul, South Korea|
|Ragini Kudchadkar||Emory University School of Medicine, Atlanta, GA, USA|
|James Larkin||Royal Marsden Hospital, London, UK|
|Robert R McWilliams||Mayo Clinic, Rochester, MN, USA|
|Sofia Merajver||University of Michigan, Ann Arbour, MI, USA|
|Mark Middleton||Oxford University, Oxford, UK|
|Paul Nathan||Mount Vernon Cancer Centre, Northwood, UK|
|Sylvie Negrier||Centre Léon-Bérard, Lyon, France|
|Harvey I Pass||New York University Medical Center, New York, NY, USA|
|Edith A Perez||Mayo Clinic, Jacksonville, FL, USA|
|Robert Pirker||Medical University of Vienna, Vienna, Austria|
|Emilio Porfiri||Queen Elizabeth Hospital Birmingham, Birmingham, UK|
|David Quinn||University of Southern California, Los Angeles, CA, USA|
|Bhupendra Rawal||Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, MA, USA|
|Joseph D Rosenblatt||University of Miami, Miami, FL, USA|
|Frances Shepherd||Princess Margaret Hospital, Toronto, ON, Canada|
|Josep Tabernero||Vall d'Hebron University Hospital, Barcelona, Spain|
|Scott Tagawa||Weill Cornell Medicine, New York, NY, USA|
|Bruno Vincenzi||University Campus Bio-Medico, Rome, Italy|
|Toni Wozniak||Wayne State University, Detroit, MI, USA|
|Andrew X Zhu||Massachusetts General Hospital Cancer Center, Boston, MA, USA|
- Open Access
- Article processing charge (APC)
- What do we publish?
3.1 Aims & scope
3.2 Article types
3.3 Writing your paper
- Editorial policies
4.1 Peer Review Policy
4.5 Declaration of conflicting interests
4.6 Research ethics and patient consent
4.7 Clinical Trials
4.8 Reporting guidelines
- Publishing policies
5.1 Publication ethics
5.2 Contributor's publishing agreement
- Preparing your manuscript
6.1 Word processing formats
6.2 Artwork, figures and other graphics
6.3 Supplemental material
6.4 Reference style
6.5 English language editing services
- Submitting your manuscript
7.1 How to submit your manuscript
7.2 Title, keywords and abstracts
7.3 Information required for completing your submission
- On acceptance and publication
8.1 SAGE Production
8.2 Online publication
8.3 Promoting your article
- Further information
This Journal is a member of the Committee on Publication Ethics.
This Journal recommends that authors follow the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals formulated by the International Committee of Medical Journal Editors (ICMJE).
Please read the guidelines below then visit the journal’s submission site https://mc.manuscriptcentral.com/tao to upload your manuscript. Please note that manuscripts not conforming to these guidelines may be returned. Remember you can log in to the submission site at any time to check on the progress of your paper through the peer review process.
Only manuscripts of sufficient quality that meet the aims and scope of Therapeutic Advances in Medical Onocology will be reviewed. As part of the submission process you will be required to warrant that you are submitting your original work, that you have the rights in the work, that you are submitting the work for first publication in the Journal and that it is not being considered for publication elsewhere and has not already been published elsewhere, and that you have obtained and can supply all necessary permissions for the reproduction of any copyright works not owned by you.
Therapeutic Advances in Medical Onocology may accept submissions of papers that have been posted on pre-print servers; please alert the Editorial Office when submitting (contact details are at the end of these guidelines) and include the DOI for the preprint in the designated field in the manuscript submission system. Authors should not post an updated version of their paper on the preprint server while it is being peer reviewed for possible publication in the journal. If the article is accepted for publication, the author may re-use their work according to the journal's author archiving policy.
If your paper is accepted, you must include a link on your preprint to the final version of your paper.
Therapeutic Advances in Medical Onocology is an open access, peer-reviewed journal. Each article accepted by peer review is made freely available online immediately upon publication, is published under a Creative Commons license and will be hosted online in perpetuity. Publication costs of the journal are covered by the collection of article processing charges which are paid by the funder, institution or author of each manuscript upon acceptance. There is no charge for submitting a paper to the journal.
If, after peer review, your manuscript is accepted for publication, a one-time article processing charge (APC) is payable. This APC covers the cost of publication and ensures that your article will be freely available online in perpetuity under a Creative Commons license.
The article processing charge (APC) is $2,000*.
*If the paying party is based in the European Union, to comply with European law, value added tax (VAT) must be added to the APC. Providing a VAT registration number will allow an institution to be exempt from paying this tax, except for UK institutions.
Before submitting your manuscript to Therapeutic Advances in Medical Onocology, please ensure you have read the Aims & Scope.
Therapeutic Advances in Medical Onocology considers the following kinds of article for publication:
- Original Articles. The Editors will consider preclinical, interventional and observational studies with clearly stated aims, well-reported methodology (including main outcome measures) and results, and a discussion of the results in the context of the published literature.
- Review Articles. These manuscripts are usually commissioned by the Editors, but the following types of high-quality review will be considered:
(a) General reviews that provide a synthesis of an area that fits within the aims and scope of the journal;
(b) Perspective reviews – review articles that address important new areas of general interest and afford the author the opportunity to present a forward-looking perspective on the topic;
(c) Drug reviews – review articles focusing on the available evidence for the use of a particular drug or combination therapy.
- Systematic Reviews. These should answer a specific research question and be reported according to the PRISMA guidelines. They should also include a PRISMA flow chart as a cited figure and a completed PRISMA checklist as a supplementary file (please see section 4.8).
- Meta-analyses. These should answer a specific research question and be reported according to the PRISMA guidelines. They should also include a PRISMA flow chart as a cited figure and a completed PRISMA checklist as a supplementary file (please see section 4.8).
- Case Reports. These structured reports should describe an unusual case and include a full review of the pertinent literature and a section on implications for clinical care.
- Case Series. These descriptive structured reports (which do not involve formal hypotheses or pre-specified methodology or analyses) of a small group of patients should include a full review of the pertinent literature and a section on implications for clinical care.
- Study Protocols. These can be for forthcoming or ongoing research. Information on trial registration (where applicable) and ethics approval should be included in the manuscript.
- Letters to the Editor. These brief opinion pieces should be as concise as possible, usually no more than 1000 words.
The journal considers the results of rigorous, well-designed studies that demonstrate “no effect” or that fail to replicate previous work (“negative data”) as important to the advancement of science. Therapeutic Advances in Medical Onocology welcomes short reports on null or negative results as long as the papers are based on strong hypothesis testing.
The SAGE Author Gateway has some general advice on how to get published, plus links to further resources.
3.3.1 Making your article discoverable
For information and guidance on how to make your article more discoverable, visit our Gateway page on How to Help Readers Find Your Article Online
The journal's policy is to obtain at least two independent reviews of each article. Therapeutic Advances in Medical Onocology operates a conventional single-blind reviewing policy in which the reviewer's name is always concealed from the submitting author. Referees will be encouraged to provide substantive, constructive reviews that provide suggestions for improving the work and distinguish between mandatory and non-mandatory recommendations. All manuscripts accepted for publication are subject to editing for presentation, style and grammar. Any major redrafting is agreed with the author but the Editor's decision on the text is final.
The Editor or members of the Editorial Board may occasionally submit their own manuscripts for possible publication in the journal. In these cases, the peer review process will be managed by alternative members of the Board and the submitting Editor/Board member will have no involvement in the decision-making process.
Papers should only be submitted for consideration once consent is given by all contributing authors. Those submitting papers should carefully check that all those whose work contributed to the paper are acknowledged as contributing authors. The list of authors should include all those who can legitimately claim authorship. This is all those who:
- Made a substantial contribution to the concept or design of the work; or acquisition, analysis or interpretation of data,
- Drafted the article or revised it critically for important intellectual content,
- Approved the version to be published,
- Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content.
Authors should meet the conditions of all of the points above. Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content. When a large, multicentre group has conducted the work, the group should identify the individuals who accept direct responsibility for the manuscript. These individuals should fully meet the criteria for authorship.
Acquisition of funding, collection of data, or general supervision of the research group alone does not constitute authorship, although all contributors who do not meet the criteria for authorship should be listed in the Acknowledgments section. Please refer to the International Committee of Medical Journal Editors (ICMJE) authorship guidelines for more information on authorship.
All contributors who do not meet the criteria for authorship should be listed in an Acknowledgements section. Examples of those who might be acknowledged include a person who provided purely technical help, or a department chair who provided only general support.
4.3.1 Writing assistance
Individuals who provided writing assistance, e.g. from a specialist communications company, do not qualify as authors and so should be included in the Acknowledgements section. Authors must disclose any writing assistance – including the individual’s name, company and level of input – and identify the entity that paid for this assistance. It is not necessary to disclose use of language polishing services.
Any acknowledgements should appear first at the end of your article prior to your Declaration of Conflicting Interests (if applicable), any notes and your References.
Therapeutic Advances in Medical Onocology requires all authors to acknowledge their funding in a consistent fashion under a separate heading. Please visit the Funding Acknowledgements page on the SAGE Journal Author Gateway to confirm the format of the acknowledgment text in the event of funding, or state that: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
It is the policy of Therapeutic Advances in Medical Onocology to require a declaration of conflicting interests from all authors enabling a statement to be carried within the paginated pages of all published articles. Please ensure that a ‘Declaration of Conflicting Interests’ statement is included at the end of your manuscript, after any acknowledgements and prior to the references. If no conflict exists, please state that ‘The Author(s) declare(s) that there is no conflict of interest’. For guidance on conflict of interest statements, please see the ICMJE recommendations.
Medical research involving human subjects must be conducted according to the World Medical Association Declaration of Helsinki.
Submitted manuscripts should conform to the ICMJE Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals, and all papers reporting animal and/or human studies must state in the methods section that the relevant Ethics Committee or Institutional Review Board provided (or waived) approval. Please ensure that you have provided the full name and institution of the review committee, in addition to the approval number.
For research articles, authors are also required to state in the methods section whether participants provided informed consent and whether the consent was written or verbal.
Information on informed consent to report individual cases or case series should be included in the manuscript text. A statement is required regarding whether written informed consent for patient information and images to be published was provided by the patient(s) or a legally authorized representative. Please do not submit the patient’s actual written informed consent with your article, as this in itself breaches the patient’s confidentiality. The Journal requests that you confirm to us, in writing, that you have obtained written informed consent but the written consent itself should be held by the authors/investigators themselves, for example in a patient’s hospital record. The confirmatory letter may be uploaded with your submission as a separate file.
Please also refer to the ICMJE Recommendations for the Protection of Research Participants
All research involving animals submitted for publication must be approved by an ethics committee with oversight of the facility in which the studies were conducted. The journal has adopted the Consensus Author Guidelines on Animal Ethics and Welfare for Veterinary Journals published by the International Association of Veterinary Editors.
Therapeutic Advances in Medical Onocology conforms to the ICMJE requirement that clinical trials are registered in a WHO-approved public trials registry at or before the time of first patient enrolment as a condition of consideration for publication. The trial registry name and URL, and registration number must be included at the end of the abstract.
The relevant EQUATOR Network reporting guidelines should be followed depending on the type of study. For example, all randomized controlled trials submitted for publication should include a completed CONSORT flow chart as a cited figure and the completed CONSORT checklist should be uploaded with your submission as a supplementary file. Systematic reviews and meta-analyses should include the completed PRISMA flow chart as a cited figure and the completed PRISMA checklist should be uploaded with your submission as a supplementary file. The EQUATOR wizard can help you identify the appropriate guideline.
Other resources can be found at NLM’s Research Reporting Guidelines and Initiatives.
SAGE is committed to upholding the integrity of the academic record. We encourage authors to refer to the Committee on Publication Ethics’ International Standards for Authors and view the Publication Ethics page on the SAGE Author Gateway.
Therapeutic Advances in Medical Onocology and SAGE take issues of copyright infringement, plagiarism or other breaches of best practice in publication very seriously. We seek to protect the rights of our authors and we always investigate claims of plagiarism or misuse of published articles. Equally, we seek to protect the reputation of the journal against malpractice. Submitted articles may be checked with duplication-checking software. Where an article, for example, is found to have plagiarized other work or included third-party copyright material without permission or with insufficient acknowledgement, or where the authorship of the article is contested, we reserve the right to take action including, but not limited to: publishing an erratum or corrigendum (correction); retracting the article; taking up the matter with the head of department or dean of the author's institution and/or relevant academic bodies or societies; or taking appropriate legal action.
5.1.2 Prior publication
If material has been previously published, it is not generally acceptable for publication in a SAGE journal. However, there are certain circumstances where previously published material can be considered for publication. Please refer to the guidance on the SAGE Author Gateway or if in doubt, contact the Editor at the address given below.
Before publication SAGE requires the author as the rights holder to sign a Journal Contributor’s Publishing Agreement. Therapeutic Advances in Medical Onocology publishes manuscripts under Creative Commons licenses. The standard license for the journal is Creative Commons by Attribution Non-Commercial (CC BY-NC), which allows others to re-use the work without permission as long as the work is properly referenced and the use is non-commercial. For more information, you are advised to visit SAGE's OA licenses page Alternative license arrangements are available, for example, to meet particular funder mandates, made at the author’s request.
The preferred format for your manuscript is Word. LaTeX files are also accepted. Word and (La)Tex templates are available on the Manuscript Submission Guidelines page of our Author Gateway.
For guidance on the preparation of illustrations, pictures and graphs in electronic format, please visit SAGE’s Manuscript Submission Guidelines
Figures supplied in colour will appear in colour online.
This journal is able to host additional materials online (e.g. datasets, podcasts, videos, images etc.) alongside the full-text of the article. For more information please refer to our guidelines on submitting supplemental files.
Therapeutic Advances in Medical Onocology adheres to the SAGE Vancouver reference style. Please review the guidelines on SAGE Vancouver to ensure your manuscript conforms to this reference style.
Authors seeking assistance with English language editing, translation, or figure and manuscript formatting to fit the journal’s specifications should consider using SAGE Language Services. Visit SAGE Language Services on our Journal Author Gateway for further information.
Therapeutic Advances in Medical Onocology is hosted on SAGE Track, a web based online submission and peer review system powered by ScholarOne™ Manuscripts. Visit https://mc.manuscriptcentral.com/tao to login and submit your article online.
IMPORTANT: Please check whether you already have an account in the system before trying to create a new one. If you have reviewed or authored for the journal in the past year it is likely that you will have had an account created. For further guidance on submitting your manuscript online please visit ScholarOne Online Help.
Please supply a title, short title, an abstract and keywords to accompany your article. The title, keywords and abstract are key to ensuring readers find your article online through online search engines such as Google. Please refer to the information and guidance on how best to title your article, write your abstract and select your keywords by visiting the SAGE Journal Author Gateway for guidelines on How to Help Readers Find Your Article Online.
Provide full contact details for the corresponding author including email, mailing address and telephone numbers. Academic affiliations are required for all co-authors. These details should be presented separately to the main text of the article to facilitate anonymous peer review.
You will be asked to provide contact details and academic affiliations for all co-authors via the submission system and identify who is to be the corresponding author. These details must match what appears on your manuscript. At this stage please ensure you have included all the required statements and declarations and uploaded any additional supplementary files (including reporting guidelines where relevant).
As part of our commitment to ensuring an ethical, transparent and fair peer review process SAGE is a supporting member of ORCID, the Open Researcher and Contributor ID. ORCID provides a unique and persistent digital identifier that distinguishes researchers from every other researcher, even those who share the same name, and, through integration in key research workflows such as manuscript and grant submission, supports automated linkages between researchers and their professional activities, ensuring that their work is recognized.
The collection of ORCID iDs from corresponding authors is now part of the submission process of this journal. If you already have an ORCID iD you will be asked to associate that to your submission during the online submission process. We also strongly encourage all co-authors to link their ORCID iD to their accounts in our online peer review platforms. It takes seconds to do: click the link when prompted, sign into your ORCID account and our systems are automatically updated. Your ORCID iD will become part of your accepted publication’s metadata, making your work attributable to you and only you. Your ORCID iD is published with your article so that fellow researchers reading your work can link to your ORCID profile and from there link to your other publications. Please note that only ORCID iDs validated prior to article acceptance will be authorized for publication, and ORCID iDs cannot be added or amended at a later stage.
Authors are responsible for obtaining permission from copyright holders for reproducing any illustrations, tables, figures or lengthy quotations previously published elsewhere. For further information including guidance on fair dealing for criticism and review, please visit our Frequently Asked Questions on the SAGE Journal Author Gateway.
If your paper is accepted for publication after peer review, you will first be asked to complete the contributor’s publishing agreement. Once your manuscript files have been checked for SAGE Production, the corresponding author will be asked to pay the article processing charge (APC) via a payment link. Once the APC has been processed, your article will be prepared for publication and can appear online within an average of 30 days. Please note that no production work will occur on your paper until the APC has been received.
Your SAGE Production Editor will keep you informed as to your article’s progress throughout the production process. Proofs will made available to the corresponding author via our editing portal SAGE Edit, or by email to the corresponding author and should be returned promptly. Authors are reminded to check their proofs carefully to confirm that all author information, including names, affiliations, sequence and contact details are correct, and that Funding and Conflict of Interest statements, if any, are accurate. Please note that if there are any changes to the author list at this stage all authors will be required to complete and sign a form authorising the change.
One of the many benefits of publishing your research in an open access journal is the speed to publication. With no page count constraints, your article will be published online in a fully citable form with a DOI number as soon as it has completed the production process. At this time it will be completely free to view and download for all.
Publication is not the end of the process! You can help disseminate your paper and ensure it is as widely read and cited as possible. The SAGE Author Gateway has numerous resources to help you promote your work. Visit the Promote Your Article page on the Gateway for tips and advice. In addition, SAGE is partnered with Kudos, a free service that allows authors to explain, enrich, share, and measure the impact of their article. Find out how to maximize your article’s impact with Kudos.
Any correspondence, queries or additional requests for information on the Manuscript Submission process should be sent to the Therapeutic Advances in Medical Onocology editorial office as follows:
Georgia Patey, email@example.com